Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.

doi:10.1038/clpt.1992.24

Back to search

Article

Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.

Clinical pharmacology and therapeutics - 1 Mar 1992

Sindrup S H, Brøsen K, Gram L F

Abstract excerpt

Steady-state plasma concentrations of paroxetine were studied at five or more paroxetine dose levels (10 to 70 mg/day) in each of 13 extensive metabolizers of sparteine and at three or four dose levels (10 to 40 mg/day) in each of three poor metabolizers of sparteine, all treated for diabetic neu...

Topics

Adult
Aged
Diabetic Neuropathies
Female
Humans
Male
Middle Aged
Oxidation-Reduction
Paroxetine
Phenotype
Piperidines
Polymorphism, Genetic
Serotonin Antagonists
Sparteine

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.